• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

转谷氨酰胺酶1（TGM1）在人类癌症中的致癌和免疫作用的泛癌分析

A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer.

作者信息

Wu Ruicheng, Li Dengxiong, Zhang Shuxia, Wang Jie, Chen Kai, Tuo Zhouting, Miyamoto Akira, Yoo Koo Han, Wei Wuran, Zhang Chi, Feng Dechao, Han Ping

机构信息

Department of Urology, Institute of Urology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.

Research Core Facilities, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.

出版信息

J Cancer Res Clin Oncol. 2024 Mar 12;150(3):123. doi: 10.1007/s00432-024-05640-6.

DOI:10.1007/s00432-024-05640-6
PMID:38472489
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10933153/
Abstract

BACKGROUND

There is currently a limited number of studies on transglutaminase type 1 (TGM1) in tumors. The objective of this study is to perform a comprehensive analysis across various types of cancer to determine the prognostic significance of TGM1 in tumors and investigate its role in the immune environment.

METHOD

Pan-cancer and mutational data were retrieved from the TCGA database and analyzed using R (version 3.6.4) and its associated software package. The expression difference and prognosis of TGM1 were examined, along with its correlation with tumor heterogeneity, stemness, mutation landscape, and RNA modification. Additionally, the relationship between TGM1 expression and tumor immunity was investigated using the TIMER method.

RESULTS

TGM1 is expressed differently in various tumors and normal samples and is associated with the overall survival and progression-free time of KIRC, ACC, SKCM, LIHC, and STES. In LICH, we found a negative correlation between TGM1 expression and 6 indicators of tumor stemness. The mutation frequencies of BLCA, LIHC, and KIRC were 1.7%, 0.3%, and 0.3% respectively. In BLCA and BRCA, there was a significant correlation between TGM1 expression and the infiltration of CD4 + T cells, CD8 + T cells, neutrophils, and dendritic cells.

CONCLUSION

TGM1 has the potential to serve as both a prognostic marker and a drug target.

摘要

背景

目前关于1型转谷氨酰胺酶（TGM1）在肿瘤中的研究数量有限。本研究的目的是对各种类型的癌症进行全面分析，以确定TGM1在肿瘤中的预后意义，并研究其在免疫环境中的作用。

方法

从TCGA数据库中检索泛癌和突变数据，并使用R（版本3.6.4）及其相关软件包进行分析。检测了TGM1的表达差异和预后，以及它与肿瘤异质性、干性、突变图谱和RNA修饰的相关性。此外，使用TIMER方法研究了TGM1表达与肿瘤免疫之间的关系。

结果

TGM1在各种肿瘤和正常样本中的表达不同，并且与肾透明细胞癌（KIRC）、腺样囊性癌（ACC）、皮肤黑色素瘤（SKCM）、肝癌（LIHC）和睾丸胚胎性癌（STES）的总生存期和无进展生存期相关。在肝癌中，我们发现TGM1表达与6个肿瘤干性指标呈负相关。膀胱癌（BLCA）、肝癌和肾透明细胞癌的突变频率分别为1.7%、0.3%和0.3%。在膀胱癌和乳腺癌（BRCA）中，TGM1表达与CD4 + T细胞、CD8 + T细胞、中性粒细胞和树突状细胞的浸润之间存在显著相关性。

结论

TGM1有潜力作为一种预后标志物和药物靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/fd508b2b139b/432_2024_5640_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/04c266e5d7dd/432_2024_5640_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/2b4f3ac4a3f8/432_2024_5640_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/66c86651e902/432_2024_5640_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/f9a02172f35c/432_2024_5640_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/d48caf548f5a/432_2024_5640_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/3aca4d6893bd/432_2024_5640_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/fd508b2b139b/432_2024_5640_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/04c266e5d7dd/432_2024_5640_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/2b4f3ac4a3f8/432_2024_5640_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/66c86651e902/432_2024_5640_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/f9a02172f35c/432_2024_5640_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/d48caf548f5a/432_2024_5640_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/3aca4d6893bd/432_2024_5640_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b493/11793418/fd508b2b139b/432_2024_5640_Fig7_HTML.jpg

相似文献

1
A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer.转谷氨酰胺酶1（TGM1）在人类癌症中的致癌和免疫作用的泛癌分析
J Cancer Res Clin Oncol. 2024 Mar 12;150(3):123. doi: 10.1007/s00432-024-05640-6.
2
A pan-cancer analysis of the oncogenic role of zinc finger protein 419 in human cancer.锌指蛋白419在人类癌症中致癌作用的泛癌分析。
Front Oncol. 2022 Dec 12;12:1042118. doi: 10.3389/fonc.2022.1042118. eCollection 2022.
3
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.泛癌分析 PARP1 改变作为预测免疫治疗效果的生物标志物及其表达水平与免疫治疗特征的关联。
Front Immunol. 2021 Aug 31;12:721030. doi: 10.3389/fimmu.2021.721030. eCollection 2021.
4
A pan-cancer analysis of the oncogenic and immunological roles of apolipoprotein F (APOF) in human cancer.泛癌症分析载脂蛋白 F (APOF) 在人类癌症中的致癌和免疫作用。
Eur J Med Res. 2023 Jun 14;28(1):190. doi: 10.1186/s40001-023-01156-w.
5
[Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].泛素特异性蛋白酶7的泛癌分析及其在瘢痕溃疡癌变中的表达变化
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2023 Jun 20;39(6):518-526. doi: 10.3760/cma.j.cn501225-20230421-00137.
6
Pan-cancer analysis of prognostic and immunological role of DTYMK in human tumors.DTYMK在人类肿瘤中的预后及免疫作用的泛癌分析
Front Genet. 2022 Sep 8;13:989460. doi: 10.3389/fgene.2022.989460. eCollection 2022.
7
Stromal Interaction Molecule 1 (STIM1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Solid Tumors.基质相互作用分子1（STIM1）是一种潜在的预后生物标志物，与实体瘤中的免疫浸润相关。
J Environ Pathol Toxicol Oncol. 2023;42(2):11-30. doi: 10.1615/JEnvironPatholToxicolOncol.2022043693.
8
Pan-cancer and single-cell analysis reveal dual roles of lymphocyte activation gene-3 (LAG3) in cancer immunity and prognosis.泛癌和单细胞分析揭示淋巴细胞激活基因 3（LAG3）在癌症免疫和预后中的双重作用。
Sci Rep. 2024 Oct 15;14(1):24203. doi: 10.1038/s41598-024-74808-4.
9
Comprehensive analysis about prognostic and immunological role of WTAP in pan-cancer.WTAP在泛癌中的预后及免疫作用的综合分析
Front Genet. 2022 Sep 6;13:1007696. doi: 10.3389/fgene.2022.1007696. eCollection 2022.
10
BRCA1-Associated Protein Is a Potential Prognostic Biomarker and Is Correlated With Immune Infiltration in Liver Hepatocellular Carcinoma: A Pan-Cancer Analysis.BRCA1相关蛋白是一种潜在的预后生物标志物，与肝细胞癌的免疫浸润相关：一项泛癌分析。
Front Mol Biosci. 2020 Nov 2;7:573619. doi: 10.3389/fmolb.2020.573619. eCollection 2020.

引用本文的文献

1
RAP1GAP is a prognostic biomarker and correlates with immune infiltrates in bladder cancer.RAP1GAP是一种预后生物标志物，与膀胱癌中的免疫浸润相关。
Discov Oncol. 2025 May 22;16(1):863. doi: 10.1007/s12672-025-02634-9.
2
Transglutaminase 1: Emerging Functions beyond Skin.转谷氨酰胺酶 1：超越皮肤的新兴功能。
Int J Mol Sci. 2024 Sep 25;25(19):10306. doi: 10.3390/ijms251910306.
3
Exploring the role of ADAMTSL2 across multiple cancer types: A pan-cancer analysis and validated in colorectal cancer.探索ADAMTSL2在多种癌症类型中的作用：一项泛癌分析并在结直肠癌中得到验证。

本文引用的文献

1
Targeting the epigenome to reinvigorate T cells for cancer immunotherapy.针对表观基因组以重振 T 细胞用于癌症免疫疗法。
Mil Med Res. 2023 Dec 4;10(1):59. doi: 10.1186/s40779-023-00496-2.
2
The Largest Chinese Cohort Study Indicates Homologous Recombination Pathway Gene Mutations as Another Major Genetic Risk Factor for Colorectal Cancer with Heterogeneous Clinical Phenotypes.最大规模的中国队列研究表明，同源重组途径基因突变是具有异质性临床表型的结直肠癌的另一个主要遗传风险因素。
Research (Wash D C). 2023 Oct 17;6:0249. doi: 10.34133/research.0249. eCollection 2023.
3
TGM1 could predict overall survival for patients with urinary bladder cancer.
Discov Oncol. 2024 Oct 9;15(1):538. doi: 10.1007/s12672-024-01401-6.
转谷氨酰胺酶1（TGM1）可以预测膀胱癌患者的总生存期。
Asian J Surg. 2023 Nov;46(11):5373-5375. doi: 10.1016/j.asjsur.2023.07.102. Epub 2023 Sep 6.
4
Cutaneous melanoma.皮肤黑素瘤。
Lancet. 2023 Aug 5;402(10400):485-502. doi: 10.1016/S0140-6736(23)00821-8. Epub 2023 Jul 24.
5
Transglutaminase 2 is associated with adverse colorectal cancer survival and represents a therapeutic target.转谷氨酰胺酶 2 与结直肠癌不良预后相关，是一个潜在的治疗靶点。
Cancer Gene Ther. 2023 Oct;30(10):1346-1354. doi: 10.1038/s41417-023-00641-y. Epub 2023 Jul 13.
6
Effect of microbiome group on immune checkpoint inhibitors in treatment of gastrointestinal tumors.微生物菌群对免疫检查点抑制剂治疗胃肠道肿瘤的影响。
Chin J Cancer Res. 2023 Jun 30;35(3):252-265. doi: 10.21147/j.issn.1000-9604.2023.03.05.
7
Comprehensive analysis of the role of immune-related PANoptosis lncRNA model in renal clear cell carcinoma based on RNA transcriptome and single-cell sequencing.基于 RNA 转录组和单细胞测序的免疫相关 PANoptosis lncRNA 模型在肾透明细胞癌中作用的综合分析。
Oncol Res. 2023 Jun 27;31(4):543-567. doi: 10.32604/or.2023.029563. eCollection 2023.
8
Expression of m6A RNA Methylation Regulators and Their Clinical Predictive Value in Intrahepatic Cholangiocarcinoma.m6A RNA 甲基化调控因子的表达及其在肝内胆管癌中的临床预测价值。
Front Biosci (Landmark Ed). 2023 Jun 27;28(6):120. doi: 10.31083/j.fbl2806120.
9
A pan-cancer analysis of the oncogenic and immunological roles of apolipoprotein F (APOF) in human cancer.泛癌症分析载脂蛋白 F (APOF) 在人类癌症中的致癌和免疫作用。
Eur J Med Res. 2023 Jun 14;28(1):190. doi: 10.1186/s40001-023-01156-w.
10
Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma.免疫检查点阻断疗法在治疗肾透明细胞癌中的研究进展与展望，以 PD-1/PD-L1 为代表。
Oncol Res. 2023 May 24;31(3):255-270. doi: 10.32604/or.2023.027942. eCollection 2023.